RESUMO
Buruli ulcer and cutaneous leishmaniasis both have the similar cutaneous clinical presentation. Therefore, relying on clinical diagnosis can be challenging. We present a case of 45 years old woman diagnosed with cutaneous leishmaniasis, confirmed by skin biopsy. She received different modalities of anti-leishmanial treatment (fluconazole 450mg daily for 4 weeks, sodium stibogluconate (SSG) followed by thermal therapy, SSG/IV 20mg/kg for 30 days combined with paromomycin 15mg/kg IM for 17 days). These treatments were associated with partial improvement of the ulcer and failure of healing. A second biopsy demonstrated the presence of Mycobacterium ulcerans and hence the diagnosis of Buruli ulcer as a cause of the delayed healing of the ulcer. M. ulcerans releases a toxin known as mycolactone, which decreases immune system function and results in tissue death. M. ulcerans, is regarded as the third most prevalent Mycobacterium after M. tuberculosis and M. leprae. Treatment with streptomycin intramuscular injections 1g daily and rifampicin 600mg daily for 8 weeks was associated with complete healing of the ulcer. To our knowledge, this is the first report that describes the co-infection of Buruli ulcer and cutaneous leishmaniasis in Sudan.
Assuntos
Úlcera de Buruli , Coinfecção , Leishmaniose Cutânea , Antibacterianos/uso terapêutico , Antiparasitários/uso terapêutico , Úlcera de Buruli/complicações , Úlcera de Buruli/diagnóstico , Úlcera de Buruli/tratamento farmacológico , Coinfecção/diagnóstico , Coinfecção/tratamento farmacológico , Feminino , Humanos , Leishmaniose Cutânea/complicações , Leishmaniose Cutânea/diagnóstico , Leishmaniose Cutânea/tratamento farmacológico , Pessoa de Meia-Idade , Mycobacterium ulcerans , SudãoAssuntos
Antiparasitários/uso terapêutico , Filariose/tratamento farmacológico , Ivermectina/uso terapêutico , Dermatopatias Parasitárias/tratamento farmacológico , Antiparasitários/efeitos adversos , Contraindicações de Medicamentos , Dermatologia , Resistência a Medicamentos , Quimioterapia Combinada , Humanos , Ivermectina/efeitos adversos , Estrongiloidíase/tratamento farmacológicoAssuntos
Antiparasitários/uso terapêutico , Hanseníase/tratamento farmacológico , Esteroides/administração & dosagem , Strongyloides stercoralis/isolamento & purificação , Estrongiloidíase/prevenção & controle , Animais , Esquema de Medicação , Humanos , Hospedeiro Imunocomprometido/efeitos dos fármacos , Ivermectina/uso terapêutico , Hanseníase/diagnóstico , Esteroides/efeitos adversos , Estrongiloidíase/induzido quimicamente , Estrongiloidíase/diagnósticoRESUMO
Crusted scabies is a less common variant of scabies that is highly contagious, difficult to treat and involves infestation by Sarcoptes scabiei var. hominis. The classical clinical presentation includes crusted, scaly and generally non-pruritic lesions usually located on the head, neck, palmar, plantar and periungual region. It was first described in Norway in 1848 in patients with leprosy who presented with crusted lesions. In this study, we report the case of a patient with crusted scabies with florid clinical manifestations and chronic liver disease due to hepatitis B and delta virus infection.
Assuntos
Doença Hepática Terminal/virologia , Vírus da Hepatite B , Vírus Delta da Hepatite , Escabiose/tratamento farmacológico , Escabiose/patologia , Antiparasitários/uso terapêutico , Doença Hepática Terminal/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Escabiose/imunologia , Resultado do TratamentoRESUMO
Abstract: Crusted scabies is a less common variant of scabies that is highly contagious, difficult to treat and involves infestation by Sarcoptes scabiei var. hominis. The classical clinical presentation includes crusted, scaly and generally non-pruritic lesions usually located on the head, neck, palmar, plantar and periungual region. It was first described in Norway in 1848 in patients with leprosy who presented with crusted lesions. In this study, we report the case of a patient with crusted scabies with florid clinical manifestations and chronic liver disease due to hepatitis B and delta virus infection.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Escabiose/patologia , Escabiose/tratamento farmacológico , Vírus Delta da Hepatite , Vírus da Hepatite B , Doença Hepática Terminal/virologia , Escabiose/imunologia , Resultado do Tratamento , Doença Hepática Terminal/complicações , Antiparasitários/uso terapêuticoRESUMO
INTRODUCTION: Strongyloides stercoralis is a globally distributed nematode that causes diverse clinical symptoms in humans. Spain, once considered an endemic country, has experienced a recent increase in imported cases. The introduction of serology helps diagnosis and is currently replacing microbiological techniques in some settings, but its sensitivity is variable and can be low in immunocompromised patients. Diagnosis can only be confirmed by identification of larvae. Often, this "gold standard" can only be achieved in severe cases, such as disseminated S.stercoralis infection, or S.stercoralis hyperinfection syndrome, where parasite load is high. In addition, these clinical presentations are not well-defined. Our aim is to describe severe cases of S.stercoralis, their epidemiological profile, and their clinical details. METHODS: An observational retrospective study of disseminated S.stercoralis infection, or hyperinfection syndrome. Inclusion criteria: aged over 18, with a diagnosis of disseminated S.stercoralis infection, or hyperinfection syndrome, confirmed by visualization of larvae. Patients were identified through revision of clinical records for the period 2000-2015, in collaboration with eight reference centers throughout Spain. RESULTS: From the period 2000-2015, eighteen cases were identified, 66.7% of which were male, with a median age of 40 (range 21-70). Most of them were foreigners (94.4%), mainly from Latin America (82.3%) or Western Africa (17.6%). Only one autochthonous case was identified, from 2006. Immunosuppressive conditions were present in fourteen (77%) patients, mainly due steroids use and to retroviral coinfections (four HIV, two HTLV). Transplant preceded the clinical presentation in four of them. Other comorbidities were coinfection with HBV, Trypanosoma cruzi, Mycobacterium leprae or Aspergillus spp. All presented with digestive disorders, with 55.6% also presenting malaise. 44.4% of cases had fever, 27.8% skin complaints, and 16.7% respiratory or neurological disorders. One patient presented anemia, and one other nephrotic syndrome. Diagnosis was confirmed by identification of larvae in fresh stool samples (n = 16; 88.9%), concentration techniques (n = 6; 33.3%), larval culture (n = 5; 29.4%), or digestive biopsies (n = 8; 44%). S.stercoralis forms were identified during necropsy in one case. In addition, ten (55%) had a positive serology. All the cases were treated with ivermectin, six (33%) also received albendazole and one case received thiabendazole followed by ivermectin. All needed inpatient management, involving a mean hospitalization stay of 25 days (range 1-164). Two cases received intensive care and eventually died. CONCLUSIONS: Only eighteen cases of disseminated S.stercoralis infection/hyperinfection syndrome were identified from the 15-year period, most of which were considered to have been imported cases. Among those, immunosuppression was frequent, and mortality due to S.stercoralis was lower than previously described.
Assuntos
Doenças Transmissíveis Importadas/terapia , Gerenciamento Clínico , Strongyloides stercoralis/efeitos dos fármacos , Estrongiloidíase/epidemiologia , Estrongiloidíase/terapia , Adulto , Idoso , Albendazol/administração & dosagem , Albendazol/uso terapêutico , Animais , Antiparasitários/administração & dosagem , Antiparasitários/uso terapêutico , Doenças Transmissíveis Importadas/tratamento farmacológico , Doenças Transmissíveis Importadas/epidemiologia , Doenças Transmissíveis Importadas/parasitologia , Comorbidade , Emigrantes e Imigrantes , Fezes/parasitologia , Feminino , Humanos , Hospedeiro Imunocomprometido , Ivermectina/administração & dosagem , Ivermectina/uso terapêutico , Larva/fisiologia , Masculino , Pessoa de Meia-Idade , Encaminhamento e Consulta , Estudos Retrospectivos , Espanha/epidemiologia , Strongyloides stercoralis/isolamento & purificação , Estrongiloidíase/diagnóstico , Estrongiloidíase/tratamento farmacológico , Adulto JovemRESUMO
La lepra (enfermedad de Hansen) es una enfermedad granulomatosa crónica que afecta a la piel y a los nervios, fundamentalmente, producida por Mycobacterium leprae. Se considera un proceso preerradicado en España, con una prevalencia de 0,1 casos por 10.000 habitantes. Se ha visto un discreto incremento debido al fenómeno de inmigración desde países con mayor prevalencia de este proceso. El tratamiento que se emplea es una combinación de fármacos como rifampicina, dapsona y clofazimina (AU)
Leprosy (Hansen's disease) is a chronic granulomatous disease affecting the skin and nerves that is mainly produced by Mycobacterium leprae. It is considered a pre-eradicated condition in Spain, with a prevalence rate of 0.1 cases per 10,000 inhabitants. A slight increase has been observed due to the phenomenon of immigration from countries with higher prevalence of this condition. Current treatments used share a common base made up of several combined drugs, particularly rifampicin, dapsone, and clofazimin (AU)
Assuntos
Humanos , Hanseníase/tratamento farmacológico , Combinação de Medicamentos , Emigrantes e Imigrantes/estatística & dados numéricos , Hanseníase/epidemiologia , Antibacterianos/uso terapêutico , Antiparasitários/uso terapêuticoRESUMO
OBJECTIVES: To describe the clinical and immunological features of crusted scabies in a prospectively ascertained cohort of 78 patients. METHODS: All patients requiring inpatient treatment for crusted scabies in the 'top end' of the northern territory of Australia over a 10 year period were prospectively identified. Demographics, risk factors, and immunological parameters were retrospectively compiled from their medical records and pathology databases. RESULTS: More than half the patients with crusted scabies had identifiable immunosuppressive risk factors. Eosinophilia and elevated IgE levels occurred in 58% and 96% of patients, respectively, with median IgE levels 17 times the upper limit of normal. Seventeen percent had a history of leprosy but 42% had no identifiable risk factors. There was a decrease in mortality after the introduction of a treatment protocol consisting of multiple doses of ivermectin combined with topical scabicides and keratolytic therapy. CONCLUSIONS: Crusted scabies often occurs in patients with identifiable immunosuppressive risk factors. In patients without such risk factors, it is possible that the crusted response to infection results from a tendency to preferentially mount a Th2 response. The treatment regime described was associated with a reduction in mortality. This is the largest reported case series of crusted scabies.